Last edition
News about "Bayer AG "
AskBio Completes Enrollment for Phase 2 Gene Therapy Trial Targeting Heart Failure
The GenePHIT study evaluating investigational therapy AB-1002 for heart failure with reduced ejection fraction has fully enrolled 173 patients, with initial results expected in early 2027.
Bayer AG | 02/04/2026 | By News Bureau
Bayer to Enter Molecular Imaging, Acquires Pan-Amyloid Radiotracers from Attralus
By acquiring AT-01 and AT-05 from Attralus, Bayer strengthens its molecular imaging and cardiovascular precision medicine portfolio, targeting earlier and more accurate diagnosis of amyloidosis.
Bayer AG | 14/01/2026 | By News Bureau | 191
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy